Novo Nordisk A/S (NVO) Bids Adieu to Oral Insulin, Shakes Up R&D for Growth
11/1/2016 6:18:45 AM
Novo Nordisk's new CEO won’t start till the New Year. But he’s already jumping in to reshape the company’s R&D priorities. The diabetes giant has opted to end its development of an oral form of insulin, which has long been an unattainable dream for the industry.
It’s also refocusing its pipeline to rely more upon in-licensing early stage projects and working with external academic collaborators.
comments powered by